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Background. Thismulticenterphase II study investigated
temozolomide + irinotecan (TEMIRI) treatment in chil-
dren with relapsed or refractory medulloblastoma.
Methods. Patients received temozolomide 100–
125 mg/m2/day (days 1–5) and irinotecan 10 mg/m2/
day (days 1–5 and 8–12) every 3 weeks. The primary
endpoint was tumor response within the first 4 cycles con-
firmed ≥4 weeks and assessed by an external response
review committee (ERRC). In a 2-stage Optimum
Simon design, ≥6 responses in the first 15 evaluable pa-
tients were required within the first 4 cycles for continued
enrollment; a total of 19 responses from the first 46 evalu-
able patients was considered successful.
Results. Sixty-six patients were treated. Seven responses
were recorded during stage 1 and 15 in the first 46
ERRC evaluated patients (2 complete responses and 13
partial responses). The objective response rate during
the first 4 cycles was 32.6% (95% confidence interval
[CI], 19.5%–48.0%). Median duration of response was
27.0 weeks (7.7–44.1 wk). In 63 patients evaluated by
local investigators, the objective response rate was
33.3% (95% CI, 22.0%–46.3%), and 68.3% (95% CI,
55.3%–79.4%) experienced clinical benefit. Median sur-
vival was 16.7 months (95% CI, 13.3–19.8). The most
common grade 3 treatment-related nonhematologic
adverse event was diarrhea (7.6%). Grade 3/4 treat-
ment-related hematologic adverse events included neu-
tropenia (16.7%), thrombocytopenia (12.1%), anemia
(9.1%), and lymphopenia (9%).
Conclusions. The planned study primary endpoint was
not met. However, its tolerability makes TEMIRI a suit-
able candidate chemotherapy backbone for molecularly
targeted agents in future trials in this setting.
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M
edulloblastomas are aggressive embryonal
tumors and represent the most common malig-
nant pediatric brain tumors.1,2 Standard treat-
ment includes surgery, craniospinal radiotherapy, and
chemotherapy. Despite current multimodal treatment,
prognosis remains poor, particularly in patients with re-
current or metastatic disease.1,3 The various therapeutic
options, including high-dose chemotherapy, in patients
who experience a relapse after craniospinal irradiation
have unfortunately led to only minimal increments in
progression-free survival.4,5 In the last 20 years, very
few new chemotherapy agents have been incorporated
into the therapeutic armamentarium in this setting.
However, several drugs or drug combinations have
shown moderate efficacy in phase I and phase II studies
of recurrent disease.6–10 Indeed, the identification of
treatment combinations that provide high response rates
in these patients might also prove useful during the
initial treatment of the disease.
Temozolomide was reported to be tolerable, demon-
strating activity as a single agent in patients with pediatric
malignant glioma11 and in children and adolescents with
recurrent or relapsed brain tumors, including medullo-
blastoma,10,12–15 or in combination with etoposide or
O6-benzylguanine in the same treatment setting.7,8,16
Irinotecan has demonstrated activity in pediatric patients
with relapsedor refractorysolid tumors, includingmedul-
loblastoma.9,17–19 The combination of temozolomide
with irinotecan (TEMIRI) is an attractive treatment
option, firstly, because of the different toxicity profiles as-
sociated with the individual drugs and, secondly, due to
the potential for a synergistic effect on efficacy from their
combined activities. For example, tumors with DNA mis-
match repair pathway deficiency are usually resistant to al-
kylatingagentsbutareextremelysensitive to topoisomerase
I inhibitors.20 Moreover, O6 alkylation of guanine, a direct
effectof the inhibitionofO6-alkylguanine-DNAtransferase
(MGMT) by temozolomide, induces the formation of more
topoisomerase IDNAcomplexes, thereby increasing the cy-
totoxicity of topoisomerase I inhibitors.21,22 A synergistic
effect on efficacy was demonstrated for the treatment com-
bination in xenograft models where the antitumor activity
of TEMIRI was significantly greater than that of either
agent alone and was found to be independent of tumor
MGMT expression.23,24 In clinical studies, TEMIRI dem-
onstrated tumor responses in patients with adult malignant
glioma25,26 and in childhood tumors, including neuroblas-
toma27 and Ewing’s sarcoma.28,29 Furthermore, gastroin-
testinal and hematologic adverse events (AEs) reported in
these studies were tolerable.
This large phase II international multicenter studyaimed
to assess the activity and safety profile of TEMIRI in pediat-
ric patients with recurrent or refractory medulloblastoma.
Materials and Methods
Eligibility
Patients were aged 6 months to ≤18 years with refractory
medulloblastoma in which current standard treatment
approaches had failed. Other major inclusion criteria
were: measurable primary and/or metastatic disease (at
least1bidimensionally measurable lesion [at least1 diam-
eter .10 mm] on MRI); no previous treatment with
temozolomide or irinotecan; Lansky–Play scale ≥70%
or Eastern Cooperative Oncology Group performance
status ≤1 as appropriate based on age; life expectancy
≥3 months; and adequate organ function.
Patients could not be included if they had received che-
motherapy during the previous 3 weeks or radiotherapy
ornitrosoureas during the previous6weeksor haduncon-
trolled diarrhea; a serious concomitant systemic disorder;
galactose, lactose, fructose, or glucose intolerance; hyper-
sensitivity to irinotecan, temozolomide, or any of the
excipients; and chronic inflammatory bowel disease
and/or bowel obstruction.
The study was conducted in accordance with the
Declaration of Helsinki and in compliance with
International Conference on Harmonisation good clini-
calpractice guidelines and local regulatoryethics commit-
tee guidelines. Written informed consent was required
from parent(s) or legal guardian(s) and the patients, as
appropriate, prior to study enrollment.
Study Design
This was a multicenter, single-arm, open-label phase II
study with a 2-stage Optimum Simon design30 to investi-
gate irinotecan in combination with temozolomide in
children with recurrent or refractory medulloblastoma.
According to previous data showing delayed responses
with temozolomide in pediatric brain tumors, including
medulloblastomas,10,31 the primary endpoint was an
objective tumor response during the first 4 cycles of treat-
ment, which must have been confirmed by a follow-up ob-
jective tumor response assessment obtained ≥4 weeks
after the initial documentation and was based on assess-
ment by an external response review committee
(ERRC). Secondary endpoints included confirmed best
overall tumor response (within the first 4 cycles or any
timeon treatment) basedon local investigatorassessment,
duration of tumor response, time to tumor progression
(TTP), time to treatment failure (TTF), and overall
survival (OS). The safety profile of TEMIRI was also
investigated.
Treatment
Patients received oral temozolomide 100 mg/m2/day on
days 1–5 followed by i.v. irinotecan 10 mg/m2/day on
days 1–5 and days 8–12 in 3-week cycles. The temozolo-
mide starting dosage was increased to 125 mg/m2/day at
cycle 2 in the absence of grade 3 toxicity or higher.
Patients continued study treatment for up to 1 year or
until disease progression, unacceptable toxicity, or un-
willingness to continue. After 5 cycles of treatment, pa-
tients who had not progressed may have received
irinotecan once weekly at 125 mg/m2 on days 1 and 8.
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Assessments
Response was assessed by MRI according to World
Health Organization guidelines.32 Mandatory was MRI
with at least 1 scan including T1 (with and without
contrast), T2, and fluid-attenuated inversion recovery
sequences. Response was first assessed at the end of
cycle 2. An objective tumor response during the first 4
cycles of treatment was confirmed by a response assess-
ment obtained ≥4 weeks after the initial documentation.
Continuing response/stable disease (SD) was confirmed
every2cycles (6wk)untildisease progressionor studydis-
continuation. Clinical benefit was measured as a post hoc
assessment and was defined as the proportion of patients
with a confirmed objective response and those who had
SD for .4 cycles.
Patients were followed for survival for up to 1 year
after the last dose of study treatment or discontinuation
from the study. For objective tumor response, clinical
benefit, TTP, and TTF, patients were censored if they
did not have objective or clinical evidence of progressive
disease, were removed from the study, or had additional
antitumor therapy, including radiation therapy and
surgery given as adjuvant therapy and chemotherapy reg-
imens not under study. Safety was evaluated and graded
according to the National Cancer Institute Common
Terminology Criteria for Adverse Events version 3.0.
AEs were recorded at study visits and for at least 28
days after the last dose of study treatment.
Statistical Analysis
The study had 80% power to differentiate between an un-
desirable response rate of 30% and a desirable response
rate of 50%. As part of the 2-stage Optimum Simon
design,30 an interim analysis for futility was performed
at the end of stage 1. Only if at least 6 responses were
confirmed in the first 15 evaluable patients enrolled in
stage 1 were an additional 31 evaluable patients to be
enrolled in the second stage for a total of 46 evaluable
patients; 19 confirmed responses was considered a
success.
In the primary efficacy analysis, the ERRC disease as-
sessment review determined the objective tumor responses
ofall patients; thesewere usedas the primaryassessment in
theobjective responseanalysis.The investigators’ response
assessments were also collected and were used as second-
ary assessments in the objective response analyses.
Safety was analyzed in the safety population compris-
ing all enrolled patients who were administered at least 1
dose of study medication.
The primary efficacy endpoint was evaluated in the
primary evaluable population (deemed evaluable by the
ERRC) comprising the first 46 evaluable patients (prede-
termined by the 2-stage Optimum Simon design) who
formed a subset of the safety population. Patients were
counted into the primary evaluable population consecu-
tively based on the date of first treatment with study
medication.
Secondary efficacy endpoint analyses were performed
in both the primary evaluable population and the local
evaluable population, which comprised those patients
from the safety population with measurable disease and
at least 1 tumor assessment (both by the investigator)
who had completed at least 2 cycles of study treatment
or who had progressed.
TTF, TTP, and OS were described using the Kaplan–
Meier imputation method; median times and 95% confi-
dence intervals (CIs) were calculated.
Results
Patients
Sixty-six patients were enrolled between April 2007 and
April 2010. Patient baseline demographics and disease
characteristics are shown in Table 1. Most patients were
heavily pretreated or had refractory disease while on che-
motherapy; 51 were treated at first relapse and 15 at
second or further relapse. The majority of patients were
male (68.2%), and the median age was 10.5 years
(range, 2–17 y). Most patients had classical medulloblas-
toma (84.9%), 9 patients (13.6%) had desmoplastic
disease, and 1 had an anaplastic variant of
Table 1. Patient and disease characteristics at baseline in the
safety population
Characteristics Patients, n5 66
Sex, n (%)
Male 45 (68.2)
Female 21 (31.8)
Age, y, median (range) 10.5 (2–17)
Performance status, n (%)
ECOG or equivalent Lansky–Play scale, n (%)
0 or 100–90% 39 (59.1)
1 or 80–70% 27 (40.9)
Any signs and symptoms, n (%) 54 (81.8)
Histological classification, n (%)
Classical 56 (84.9)
Desmoplastic 9 (13.6)
Anaplastic large cell variant 1 (1.5)
No medulloblastoma 1 (1.5)
Disease site, n (%)
Brain 53 (80.2)
Spinal cord 12 (18.2)
Other 1 (1.5)
No lesion reported 1 (1.5)a
Prior treatment, n (%)
Any chemotherapy 66 (100)
High-dose chemotherapy 14 (21.2)
Radiation therapy 61 (92.4)b
Craniospinal irradiation 59 (89.4)
Surgery 66 (100)
Abbreviation: ECOG, Eastern Cooperative Oncology Group.
aNo target lesion at baseline was recorded on the case report form
by the investigator and confirmed by central review.
bFive patients had not received radiation therapy at the time of
study entry; all 5 were progressive under sandwich chemotherapy.
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medulloblastoma. The target lesions were most common-
ly in the brain (80.3%).
Patient disposition and study analysis populations are
shown in Table 2. Two patients were excluded from the
local evaluable population for efficacy as having only
nonmeasurable disease, and 1 patient with presumed
relapse was subsequently considered to have had radio-
logical changes following re-review by the site 2 years
after study entry. The local evaluable population there-
fore comprised 63 patients. The primary evaluable popu-
lation comprised the first 46 evaluable patients (by the
ERRC)—in total, 48 patients were considered evaluable
by ERRC. Eighteen patients were considered not evalu-
able for the primary efficacy endpoint for reasons
including no evaluable assessments after baseline or
quality issues concerning radiological images (n ¼ 7),
no measurable disease (ie,,10 mm; n ¼ 5), no evaluable
scan at baseline (n ¼ 4), or a combination of these issues
(n ¼ 2). In addition, 1 patient, finally considered to have
radiological changes following review by the site, was
removed from the primary efficacy analysis.
Most patients (53%) discontinued treatment due to
disease progression or relapse; only 2 patients (3%) dis-
continued due to treatment-related AEs (Table 2).
Efficacy
Following ERRC assessment, 7 confirmed responses were
observed in the first 4 cycles in the first 15 evaluable
patients, allowing for continued enrollment. In the
primary evaluable population, there were 15 confirmed
objective responses (2 complete responses [CRs] and 13
partial responses [PRs]; Table 3) with an objective re-
sponse rate of 32.6% (95% CI, 19.5%–48.0%). The
study did not meet the primary endpoint of 19 confirmed
responses as planned in the protocol. However, 2 other
PRs were observed and confirmed at 23 and 27 days but
not after≥30 days; inaddition to another PR thatwasob-
served after the 4th course, these PRswere not considered.
Efficacy endpoints in the local evaluable population
are presented in Table 3. The objective response rate in
the local evaluable population was 33.3% (1 CR and 20
PRs) during the first 4 cycles. In addition, 2 patients had
PRs reassessed 21 and 23 days after the initial PR assess-
ment, thus too early to be considered as confirmed PRs;
they were considered per definition as unconfirmed PRs.
In the 46 patients of the primary evaluable population,
there was a 35% discordance between the results of the
ERRC and the local assessments; 4 PRs were reviewed
as SDs and 6 SDs were reviewed as PRs. One patient
Table 2. Patient disposition and study analysis populations
Number of
patients (%)
Study analysis populations
Safety analysis population 66
Local evaluable population 63a
Primary evaluable population 46
Patient disposition at the end of treatment
Treated patients 66 (100)
Discontinued due to
Disease progression or relapse 35 (53.0)
Completed treatment during 1 year 9 (13.6)
Patient refused to continue treatment
unrelated to adverse events
4 (6.1)
Adverse events 2 (3.0)
Protocol violation 1 (1.5)
Patient died 0
Otherb 15 (22.7)
aOne patient with presumed relapse was now considered to have
had radiological changes following re-review by the site 2 years
after study entry.
bOther reasons included: 11 patients on investigator’s/physician’s
decision (6 due to no further benefit gained, 4 no reason given, and
1 had clinical progression); 1 patient had completed 1 y of
treatment (not allowed to follow by protocol); investigator error
(treatment stopped 1 cycle early); 1 patient following good
response proceeded to high-dose chemotherapy; 1 patient
proceeded to surgery following a re-scan; 1 patient had difficulty
swallowing medication.
Table 3. Summary of the efficacy endpoint analyses
Study Population, n (%)
Evaluated by
ERRC (n5 46)
Evaluated by Local
Investigator (n5 63)
Objective responsea, n (%)
CR 2 (4.3) 1 (1.6)
PR 13 (28.3) 20 (31.7)
SD 19 (41.3) 26 (41.3)
Progressive disease 12 (26.1) 15 (23.8)
Indeterminate 0 1 (1.6)
Objective response
ratea, n (%)
15 (32.6) 21 (33.3)
95% CI 19.5–48.0 22.0–46.3
Duration of responsea
Median, wk 27.0 19.1
Range 7.7–44.1 6.9–46.6
TTP parameter
Event free at
6 mo,b %
46.2 49.6
95% CI 31.3–61.0 36.7–62.6
Median TTP, mo 4.3 5.6
95% CI 2.7–6.4 3.8–7.4
TTF parameter
Event free at
6 mo,b %
37.0 34.9
95% CI 23.0–50.9 23.1–46.7
Median TTF, mo 3.4 3.8
95% CI 2.6–6.1 2.9–5.4
Abbreviations: TTP, time to tumor progression; TTF, time to
treatment failure.
aResponses during the first 4 treatment cycles; in addition, 2
patients had PRs confirmed 21 and 23 days after the initial
assessment, thus were considered per definition as unconfirmed
PRs.
bFor both TTP and TTF, probability of being event free at 6 mo was
calculated using Kaplan–Meier imputation method.
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was considered as having a late response (1 CR after 4
cycles of treatment) by ERRC and local review.
For patients who responded within the first 4 cycles in
the primary evaluable population, the median duration of
response was 27.0 weeks (7.7–44.1 wk) and in the local
evaluable population 19.1 weeks (6.9–46.6). At any
time on treatment the median duration of response was
24.1 (7.7–44.1) and 22.4 (6.9–46.6) weeks in these pop-
ulations, respectively. Of note, 5 patients had prolonged
responses, with durations ranging from 30 to 75 weeks,
and were treated with adjuvant, consolidation,or mainte-
nance therapy following administration of TEMIRI. Of
these patients, 1 had a confirmed PR (total duration
30.1 wk) followed by radiation therapy; 1 had a con-
firmed CR (total duration 46.6 wk) followed by surgery;
1 had an unconfirmed PR (confirmed 21 days after
initial assessment, total duration 57.7 wk) followed by
surgery and radiation therapy; 1 had a PR followed by a
CR on treatment (total duration 68.9 wk) and had addi-
tional chemotherapy other than irinotecan or temozolo-
mide (busulfan and thiotepa at 6 mo after TEMIRI, and
cyclophosphamide and valproic acid 6 mo later); and 1
patient had a PR (total duration 75.0 wk) and additional
chemotherapy other than irinotecan or temozolomide
(etoposide, thiotepa, vincristine, and methotrexate 4
mo after TEMIRI).
Clinical benefit was observed in 60.9% (95% CI,
45.4%–74.9%) of patients in the primary evaluable pop-
ulation and 68.3% (95% CI, 55.3%–79.4%) of patients
in the local evaluable population.Theestimatedprobabil-
ity of remaining progression free at 6 months was 46.2%
(95% CI, 31.3%–61.0%) in the primary evaluable pop-
ulation, and median TTP was 4.3 months (95% CI,
2.7–6.4). Similar results were observed in the local evalu-
able population (49.6% [95% CI, 36.7–62.6]; median
TTP, 5.6 mo [95% CI, 3.8–7.4]).
In the 65 patients who received at least 1 dose of study
medication and who had the disease under study, the
median survival was 16.7 months (95% CI, 13.3%–
19.8%; n ¼ 65).During the follow-upperiod, 43 patients
(65.2%) received additional chemotherapy, 14 (21.2%)
had reirradiation, and 5 (7.6%) had surgery.
Exposure and Safety
The median number of cycles started was 6 (range, 1–18;
Table 4). Forty-six patients (69.7%) had at least 1 cycle
delay, and 27 patients (40.9%) had 2 or more delays
(median delay, 7 d; range, 1–31 d). Ten patients
(15.2%) had at least 1 irinotecan dose delay, and 3
(4.5%) had at least 1 temozolomide dose delay. Of 34 pa-
tients reporting any interruption or reduction of study
treatment, 19 had hematologic toxicities, 5 had gastroin-
testinal toxicities, and 6 had other toxicities. Median
relative dose intensities were 100% and 105% for irinote-
can and temozolomide, respectively.
Across the study period, 60 patients (90.9%) experi-
enced 327 AEs considered possibly related to treatment
(Table 5). The most frequently reported AEs of any
grade were gastrointestinal disorders, including diarrhea
(59.1%), vomiting (56.1%), and nausea (28.8%).
Grade 3 gastrointestinal disorders included diarrhea in
5 patients (7.6%) and vomiting and abdominal pain in 1
patient each (1.5%). Grade 3/4 treatment-related hema-
tologic disorders included neutropenia in 11 patients
(16.7%), thrombocytopenia in 8 patients (12.1%), and
anemia and lymphopenia each in 6 patients (9.1%).
Of 65 patients evaluable for laboratory abnormalities,
3 patients (4.6%) experienced grade 3 hypokalemia,
and 2 patients (3.1%) each experienced grade 3/4
alanine aminotransferase abnormalities or hyponatre-
mia. Less common grade 3 treatment-related AEs,
present only once, were weight loss, hypotension, dehy-
dration, infection, gastroenteritis, hypophosphatemia,
and aspartate aminotransferase level increase. No other
grade 4 treatment-related AEs were encountered.
Two patients permanently discontinued therapy due
to AEs other than disease progression. One patient with-
drew due to diarrhea and vomiting (considered treatment
related), and 1 patient withdrew due to serious depression
(considered unrelated). Seven patients (10.6%) died
within 28 days of the last administration of study treat-
ment due to disease progression.
Discussion
This phase II study in heavily pretreated patients is
the largest of its kind in pediatric recurrent/refractory
medulloblastoma and reported a promising response
rate (reviewed by ERRC) of 32.6% after the first 4
cycles of treatment with TEMIRI. The median duration
of response was 27 weeks (range, 7.7–44.1 wk).
Response rates after 4 cycles of treatment, and the best
overall response calculated using local investigatorassess-
ments, were similar to those reported by the ERRC.
Response was assessed within the first 4 cycles (rather
than at any time during treatment) to allow an assessment
of TEMIRI to elicit responses earlier than later.
The stringent 2-stage Optimal Simon design was
adopted to detect a response rate above 40%, which
was not met; nevertheless, the response rate of 32.6%
compares favorably with most of those previously
reported in patients receiving chemotherapy in this
setting.6,7,9,10,12–14,17,19 Indeed, we are unaware of any
similar response rate reported in a multicenter centrally
reviewed study of heavily pretreated patients with recur-
rent/refractory medulloblastoma. Moreover, clinical
Table 4. Summary of study treatment exposure
n5 66
Median number of cycles started (range) 6.0 (1–18)
Patients with ≥1 cycle delay, n (%) 46 (69.7)
Patients with .1 cycle delay, n (%) 27 (40.9)
Patients with ≥1 irinotecan dose delay, n (%) 10 (15.2)
Patients with ≥1 temozolomide dose delay, n (%) 3 (4.5)
Median (range) relative dose intensity for
irinotecan
100 (20–550)
Median (range) relative dose intensity for
temozolomide
105 (25–173)
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benefit was received in 60.9% of the primary evaluable
population and 68.3% of the local evaluable population.
Approximately 50% of patients completed at least 6
cycles of treatment.
In this analysis, duration of response was censored
at the initiation of any new antitumor therapy, including
radiation or surgery, to capture the direct benefit of
TEMIRI. Of note, however, there were 5 patients who
had prolonged responses, with durations ranging from
30 to 75 weeks, who were treated with adjuvant radiation
therapy, surgery, or consolidation or maintenance
chemotherapy following administration of TEMIRI.
Taking into account the published data, it appears
that the TEMIRI regimen leads to an improvement in
the objective response rate compared with that reported
when irinotecan (16% and 17%)9,19 and temozolomide
(14% and 16%)10,15 were administered as single agents.
Disease control also appeared to be improved in this
comparison.
Allowing for censoring of patients receiving other
antitumor therapy after receiving TEMIRI, 46.2% of
patients in the primary evaluable population were pro-
gression free at 6 months, and the median TTP was 4.3
months. Survival at 6 months was 79.7%, and median
survival was 16.7 months. While many studies in this
setting have not reported patient survival data, these
current findings (where comparable) are favorable com-
pared with many of those that have.12,14,33 In a large
study of pretreated, relapsed medulloblastoma from the
Children’s Cancer and Leukemia Group,33 40 patients
received cyclophosphamide together with surgery or
local radiotherapy, and 22 of these went on to be
treated with a high-dose chemotherapy-based strategy.
Witha median follow-up of 7.4 years, the median survival
in these 40 patients was 1.4 years and median event-free
survival was 1 year.33
The combination of irinotecan with standard temozo-
lomide was generally well tolerated and consistent with
exposure to these agents in the pediatric setting or with
the disease under study.12,17,28,29,34 Indeed, TEMIRI
was better tolerated than many high-dose chemotherapy
regimens in this setting, which are more intensive
without being as effective.
Areas of controversy remain in medulloblastoma re-
search, such as inclusion/exclusion criteria in clinical
trials. Indeed, classical WHO criteria mandate bidimen-
sionally measurable lesions with at least 1 diameter
.10 mm on an MRI scan. This is not always appropriate
in medulloblastoma with frequent thin leptomeningeal
disease. However, to measure tumor response of small
lesions also remains an issue. Thus, new consensual crite-
ria for inclusionandevaluationof earlydrug development
studies in medulloblastoma are needed.
In summary, in this phase II study in pediatric patients
with recurrent or refractory medulloblastoma, although
the TEMIRI regimen did not meet the primary efficacy
endpoint, it was well tolerated. Newly designed trials
are needed that investigate this tolerable combination as
a chemotherapy backbone in combination with molecu-
larly targeted drugs. These could include agents targeted
to platelet derived growth factor receptor (one of the
factors implicated in driving metastasis), sonic hedgehog,
or, in particular, poly (ADP-ribose) polymerase 1
inhibitors.35–39
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Anemia 1 (1.5) 2 (3.0) 6 (9.1) 0 9 (13.6)
Abbreviation: AE, adverse effect.
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